Prevalence of heavy menstrual bleeding and associations with physical health and wellbeing in low-income and middle-income countries: a multinational cross-sectional study.
Journal
The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
01
02
2023
revised:
14
07
2023
accepted:
24
08
2023
medline:
23
10
2023
pubmed:
7
10
2023
entrez:
6
10
2023
Statut:
ppublish
Résumé
Data on the prevalence of heavy menstrual bleeding in low-income and middle-income countries (LMICs) are scarce. We aimed to assess the validity of a scale to measure heavy menstrual bleeding and calculate its prevalence in southern Asia and sub-Saharan Africa, and to examine associations between heavy menstrual bleeding and health outcomes. Between Aug 2, 2021 and June 14, 2022, we surveyed 6626 women across ten cities (Meherpur and Saidpur, Bangladesh; Warangal, Narsapur, and Tiruchirappalli, India; Kathmandu, Nepal; Dakar, Senegal; Nairobi, Kenya; Kampala, Uganda; and Lusaka, Zambia), including questions on demographics, health, and the SAMANTA scale, a six-item measure of heavy menstrual bleeding. We conducted confirmatory factor analysis to assess construct validity of the SAMANTA scale, calculated the prevalence of heavy menstrual bleeding, and used regression analyses to examine associations of heavy menstrual bleeding with health outcomes. 4828 women were included in the final analytic sample. Factor analysis indicated a one-factor model representing heavy menstrual bleeding. In the pooled analytic sample, 2344 (48·6%) of 4828 women were classified as experiencing heavy menstrual bleeding, and the prevalence was lowest in Dakar (126 [38·3%] of 329 women) and Kampala (158 [38·4%] of 411 women) and highest in Kathmandu (326 [77·6%] of 420 women). Experiencing heavy menstrual bleeding was significantly associated with feeling tired or short of breath during the menstrual period (risk ratio 4·12 (95% CI 3·45 to 4·94) and reporting worse self-rated physical health (adjusted odds ratio 1·27, 95% CI 1·08 to 1·51), but was not associated with subjective wellbeing (β -3·34, 95% CI -7·04 to 0·37). Heavy menstrual bleeding is highly prevalent and adversely impacts quality of life in women across LMIC settings. Further attention is urgently needed to understand determinants and identify and implement solutions to this problem. Bill & Melinda Gates Foundation, United States Agency for International Development, National Institutes of Health.
Sections du résumé
BACKGROUND
Data on the prevalence of heavy menstrual bleeding in low-income and middle-income countries (LMICs) are scarce. We aimed to assess the validity of a scale to measure heavy menstrual bleeding and calculate its prevalence in southern Asia and sub-Saharan Africa, and to examine associations between heavy menstrual bleeding and health outcomes.
METHODS
Between Aug 2, 2021 and June 14, 2022, we surveyed 6626 women across ten cities (Meherpur and Saidpur, Bangladesh; Warangal, Narsapur, and Tiruchirappalli, India; Kathmandu, Nepal; Dakar, Senegal; Nairobi, Kenya; Kampala, Uganda; and Lusaka, Zambia), including questions on demographics, health, and the SAMANTA scale, a six-item measure of heavy menstrual bleeding. We conducted confirmatory factor analysis to assess construct validity of the SAMANTA scale, calculated the prevalence of heavy menstrual bleeding, and used regression analyses to examine associations of heavy menstrual bleeding with health outcomes.
FINDINGS
4828 women were included in the final analytic sample. Factor analysis indicated a one-factor model representing heavy menstrual bleeding. In the pooled analytic sample, 2344 (48·6%) of 4828 women were classified as experiencing heavy menstrual bleeding, and the prevalence was lowest in Dakar (126 [38·3%] of 329 women) and Kampala (158 [38·4%] of 411 women) and highest in Kathmandu (326 [77·6%] of 420 women). Experiencing heavy menstrual bleeding was significantly associated with feeling tired or short of breath during the menstrual period (risk ratio 4·12 (95% CI 3·45 to 4·94) and reporting worse self-rated physical health (adjusted odds ratio 1·27, 95% CI 1·08 to 1·51), but was not associated with subjective wellbeing (β -3·34, 95% CI -7·04 to 0·37).
INTERPRETATION
Heavy menstrual bleeding is highly prevalent and adversely impacts quality of life in women across LMIC settings. Further attention is urgently needed to understand determinants and identify and implement solutions to this problem.
FUNDING
Bill & Melinda Gates Foundation, United States Agency for International Development, National Institutes of Health.
Identifiants
pubmed: 37802092
pii: S2214-109X(23)00416-3
doi: 10.1016/S2214-109X(23)00416-3
pmc: PMC10581908
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1775-e1784Subventions
Organisme : Bill & Melinda Gates Foundation
ID : INV-028835
Pays : United States
Organisme : NIA NIH HHS
ID : U54 AG062334
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests S-RP reports funding from the Bill & Melinda Gates Foundation and Australian National Health and Medical Research Council; consultancy and speaker fees from Vifor Pharma; and consultancy fees for an external advisory role to WHO, all related to anaemia research. BAC reports research and consultancy funding from the Bill & Melinda Gates Foundation (via Columbia University) related to menstruation research. All other authors declare no competing interests.
Références
J Pediatr Adolesc Gynecol. 2016 Dec;29(6):571-576
pubmed: 26537316
Lancet. 2021 Jan 2;397(10268):26
pubmed: 33388103
BMC Womens Health. 2011 Jun 07;11(1):26
pubmed: 21649903
BMJ Open. 2022 Feb 17;12(2):e053104
pubmed: 35177447
Int J Reprod Biomed. 2018 Nov;16(11):665-678
pubmed: 30775681
BMC Womens Health. 2020 Jun 12;20(1):123
pubmed: 32532350
Reprod Health. 2020 Jun 1;17(1):81
pubmed: 32487096
PLoS Med. 2019 May 16;16(5):e1002803
pubmed: 31095568
Int J Gynaecol Obstet. 2015 Mar;128(3):196-200
pubmed: 25627706
J Psychiatr Res. 2014 Sep;56:112-9
pubmed: 24931848
Sex Reprod Health Matters. 2021 Dec;29(1):1911618
pubmed: 33910492
Acta Obstet Gynecol Scand. 1966;45(3):320-51
pubmed: 5922481
BJOG. 2004 Jan;111(1):6-16
pubmed: 14687045
J Womens Health (Larchmt). 2020 Jul;29(7):1021-1031
pubmed: 32580622
Obstet Gynecol Surv. 2017 Jun;72(6):356-376
pubmed: 28661550
BMC Womens Health. 2018 Aug 22;18(1):142
pubmed: 30134884
Lancet. 2021 Jan 16;397(10270):233-248
pubmed: 33285139
Int J Environ Res Public Health. 2018 Nov 15;15(11):
pubmed: 30445767
Obstet Gynecol. 2002 Oct;100(4):683-7
pubmed: 12383534
PLoS One. 2021 Jul 21;16(7):e0255001
pubmed: 34288971
Int J Gynaecol Obstet. 2018 Dec;143(3):393-408
pubmed: 30198563
Stud Fam Plann. 2002 Sep;33(3):261-8
pubmed: 12385087
BMC Womens Health. 2020 Feb 10;20(1):24
pubmed: 32041594
Am J Obstet Gynecol. 2019 Jun;220(6):569.e1-569.e7
pubmed: 30885768